Project Grant R21CA301039
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The U.S. National Cancer Institute (NCI) awarded a $158,290 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Kaiser Foundation Hospitals to conduct a study on "Estimating Overdiagnosis After Implementation of Lung Cancer Screening in Community-Based Healthcare Systems." This 2-year project, running from July 2024 to July 2026, aims to produce estimates of overdiagnosis among patients diagnosed with lung cancer who participated in lung cancer...
- This $658,743 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Kaiser Foundation Hospitals aims to develop and validate prediction models for trajectories of function, cognition, and quality of life among adults aged 65 and older with advanced non-small cell lung cancer during up to 6 months of chemotherapy and/or immunotherapy. The 5-year project builds on an ongoing observational cohort study of 130 older adults with advanced lung...
- The National Cancer Institute (NCI) awarded a $323,548 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on optimizing lung cancer staging and treatment decisions. The 20-month project aims to compare two lymph node biopsy procedures - endobronchial ultrasound guided transbronchial node aspiration (EBUS) and mediastinoscopy - to assess their ability to detect the extent of cancer...
- The National Cancer Institute awarded a $140,130 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Elucidating Thiol Reductive Stress in Lung Cancer Growth and Metastasis." The award period is from March 1, 2025, to February 28, 2027. This project grant supports research to investigate the impact of reductive stress, a specific vulnerability in a subset...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $602,315.00 in funding to the University of Colorado-Denver to validate the human relevance of a novel mouse model of lung squamous cell carcinoma (SCC) premalignancy and to use this model to screen and test lung cancer prevention agents. The project aims to incorporate tissue from the improved mouse model into a bioengineered precision cut lung slice model to maintain the...
- This $2,991,283 Project Grant was awarded on September 23, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida. The grant will fund a two-pronged research approach to (1) leverage a large electronic health record database to characterize trends and outcomes of lung cancer screening among people with and without HIV in the U.S., and (2) partner with community clinics serving...
- This federal Project Grant award of $505,613, provided by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research), will support the development of statistical and computational approaches to harness genomic data and translate findings into precision prevention strategies for cancer. The key objectives are to: Develop deep learning-based methods to identify tumor subtypes linked to adverse outcomes and robust data integration approaches to assess associations between...
- This $433,185 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health federal grant program (CFDA 93.113) will support research by the Harvard T.H. Chan School of Public Health to examine the associations between ambient particle radioactivity (PR) exposure and lung cancer survival. The study aims to assess the effects of pre- and post-diagnosis exposures to PR on overall and progression-free survival among lung cancer...
- This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
- The federal Project Grant was awarded by the National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The $764,448 grant was awarded to Cereus Diagnostics Corp. on August 1, 2025 to develop Lung-FAST, a rapid and cost-effective PCR-based test that can detect clinically actionable genetic mutations in lung cancer samples with high accuracy, even from small biopsy samples. The key...